Polynovo Ltd
Company Profile
Business description
Polynovo earns majority of its revenue from U.S sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita's RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months.
Contact
320 Lorimer Street
Unit 2
Port MelbourneVIC3207
AUST: +61 386814050
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
Employees
8
Polynovo Ltd News & Analysis
stocks
ASX healthcare stocks shrug off new tariff threat
stocks
The ASX’s most shorted stocks
stocks
Will CEO departure upend ASX healthcare leader?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,901.20 | 26.70 | 0.30% |
| CAC 40 | 8,140.59 | 50.31 | 0.62% |
| DAX 40 | 25,537.75 | 135.47 | 0.53% |
| Dow JONES (US) | 51,461.90 | 631.21 | -1.21% |
| FTSE 100 | 10,688.47 | 30.34 | 0.28% |
| HKSE | 24,713.78 | 46.54 | 0.19% |
| NASDAQ | 25,978.43 | 3.14 | -0.01% |
| Nikkei 225 | 64,076.13 | 153.13 | 0.24% |
| NZX 50 Index | 13,685.58 | 62.86 | 0.46% |
| S&P 500 | 7,551.81 | 33.92 | -0.45% |
| S&P/ASX 200 | 8,727.20 | 30.70 | 0.35% |
| SSE Composite Index | 3,891.43 | 0.17 | -0.00% |